Daewon Pharmaceutical also hits the accelerator on oral obesity drug development
Predicted impact: Low
Oral obesity drug development updates repeat earlier clinical news; early-stage, no revenue size given.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.